

Title (en)  
ANTHRAX LETHAL FACTOR INHIBITS TUMOR GROWTH AND ANGIOGENESIS

Title (de)  
ANTHRAX-LETALFAKTOR HEMMT TUMORWACHSTUM UND ANGIOGENESE

Title (fr)  
FACTEUR LETAL DE L'ANTHRAX INHIBANT LA CROISSANCE TUMORALE ET L'ANGIOGENESE

Publication  
**EP 1377312 A4 20041006 (EN)**

Application  
**EP 02725277 A 20020322**

Priority  
• US 0208656 W 20020322  
• US 27762501 P 20010322

Abstract (en)  
[origin: WO02076496A1] A method for inhibiting cell angiogenesis comprises contacting cells associated with undesired angiogenesis with an effective amount of an inhibitor of MEK or of an enzyme that is a member of the MAPK family. MEK inhibitors include MEK-directed proteases such as Bacillus anthracis lethal factor or a functional derivative thereof. Organic small molecule inhibitors of MEK include PD98059, U0126 and PD184352. The above contacting may be performed in vivo, in a human or other mammalian subject. Also included is a method to treat a mammalian subject having a disease or condition associated with undesired angiogenesis or neovascularization, comprising administering to the subject an effective amount of a pharmaceutical composition that comprises an inhibitor of MEK or of an enzyme that is a member of the MAPK family, as noted above, and pharmaceutically acceptable carrier or excipient. The treatment method is useful for a disease or condition such as tumor growth, tumor invasion or tumor metastasis, wherein the angiogenesis inhibition results in reduction in size or growth rate of the tumor or its destruction.

IPC 1-7  
**A61K 38/48**; **A01N 43/32**; **A01N 43/50**; **A01N 37/18**; **A01N 31/08**

IPC 8 full level  
**A61K 38/48** (2006.01)

CPC (source: EP)  
**A61K 31/166** (2013.01); **A61K 31/352** (2013.01); **A61K 31/4439** (2013.01); **A61K 38/4886** (2013.01)

Citation (search report)  
• [X] US 6147107 A 20001114 - DENT PAUL [US], et al  
• [X] DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 1999 (1999-10-01), PRICE DAVID T ET AL: "Activation of extracellular signal-regulated kinase in human prostate cancer", XP002279050, Database accession no. PREV199900481092  
• [X] DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2000 (2000-11-16), BONATI ANTONIO ET AL: "Selective inhibition of MEK1 kinase downmodulates ERK activity and proliferation of AML blasts", XP002279051, Database accession no. PREV200100301863 & JOURNAL OF UROLOGY, vol. 162, no. 4, October 1999 (1999-10-01), pages 1537 - 1542, ISSN: 0022-5347 & BLOOD, vol. 96, no. 11 Part 1, 16 November 2000 (2000-11-16), 42nd Annual Meeting of the American Society of Hematology; San Francisco, California, USA; December 01-05, 2000, pages 306a, ISSN: 0006-4971  
• See references of WO 02076496A1

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)  
**WO 02076496 A1 20021003**; AU 2002255852 B2 20061109; CA 2442015 A1 20021003; EP 1377312 A1 20040107; EP 1377312 A4 20041006

DOCDB simple family (application)  
**US 0208656 W 20020322**; AU 2002255852 A 20020322; CA 2442015 A 20020322; EP 02725277 A 20020322